logo
Plus   Neg
Share
Email

Biogen Added To Goldman's Conviction List On Alzheimer's Promise

Goldman Sachs added Biogen Inc. (BIIB) to its Americas Conviction List on Wednesday, noting that Biogen's Alzheimer's drug, aducanumab, "could be one of the first disease-modifying drugs to reach the market."

"On BIIB's base [multiple sclerosis] franchise, we view investor concerns on competition and pricing as overblown," Flynn said. "Finally, BIIB has a relatively under-leverage balance sheet, and we expect [free cash flow yield] and US cash to grow."

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Follow RTT